# GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma

> **NCT06921317** · PHASE1,PHASE2 · RECRUITING · sponsor: **IVIEW Therapeutics Inc.** · enrollment: 6 (estimated)

## Conditions studied

- Primary Open-Angle Glaucoma (POAG)

## Interventions

- **DRUG:** GVB-2001-high dose
- **DRUG:** GVB-2001-low dose

## Key facts

- **NCT ID:** NCT06921317
- **Lead sponsor:** IVIEW Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06921317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06921317, "GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06921317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*